A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Clinical trial NCT00558207 · COMPLETED
Trial details
- NCT number
- NCT00558207
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-11-01
- Primary completion
- 2008-04-01
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.